К содержанию
Dr. Tara EinullaevaMedical oncologist

Treatment 7 min

Testicular cancer: chemotherapy, surveillance and why the disease is so often curable

Testicular germ cell tumours: seminoma and non-seminoma, markers AFP, hCG and LDH, IGCCCG risk groups, BEP regimen, surveillance in stage I, fertility preservation and long-term effects.

Written and medically reviewed by

Dr. Tara Einullaeva

Medical oncologist, 9 years in practice. Credentials · reviewed 31 October 2026

Testicular cancer affects mostly young men and is one of the few tumours that is curable in most cases even with metastases. This is possible thanks to sensitivity to platinum drugs and clear treatment standards. But these standards must be followed correctly: from markers to the number of chemotherapy cycles and the duration of follow-up.

In this article I explain what diagnosis consists of, how the types of tumour differ, how the choice between surveillance and chemotherapy is made, what the BEP regimen is, how to preserve fertility and which long-term effects are worth knowing.

What kind of tumour this is

Most testicular tumours (about 90–95%) are germ cell tumours. They fall into two big groups:

Seminoma Non-seminomatous tumours
What it is One cell type Embryonal carcinoma, yolk sac tumour, choriocarcinoma, teratoma (often mixed)
Growth rate Usually slower More often faster
AFP Not raised Often raised
hCG Sometimes slightly raised Often raised
Radiotherapy Sensitive Not used
Treatment of advanced disease Platinum chemotherapy Platinum chemotherapy, often with surgery to remove residual nodes

Other tumours (from stromal cells) are less common and are treated differently.

How diagnosis begins

  1. Scrotal ultrasound, which shows the nature of the mass.
  2. Marker tests: AFP, β-hCG, LDH before surgery (AFP, tumour markers).
  3. Radical inguinal orchiectomy: removal of the testicle through a cut in the groin. It is both diagnosis and the first step of treatment. Biopsy through the scrotum or needle puncture is not done because it raises the risk of spread.
  4. CT of the chest, abdomen and pelvis for staging.
  5. Repeat markers after surgery: if they were raised, their course determines stage and tactics.
  6. Sperm banking before surgery and chemotherapy (if possible), because treatment can affect fertility: fertility preservation before chemotherapy.

If a tumour has been found and markers were not measured before surgery, this is not a reason to panic, but it is important to have the tests done as soon as possible and discuss the results.

Stage I: surveillance or treatment

If after surgery CT shows no metastases and markers have normalised, this is stage I. There are options:

Stage I seminoma:

  • surveillance (check-ups, CT and markers on schedule): suitable for many patients but requires discipline;
  • one course of carboplatin;
  • radiotherapy to the retroperitoneal nodes (used less often today).

Stage I non-seminomatous tumour:

  • surveillance if the risk of recurrence is low;
  • one to two cycles of BEP at higher risk (for example with invasion into lymphatic or blood vessels);
  • retroperitoneal lymph node dissection in some centres.

The choice depends on risk features in the pathology and on how ready you are for regular follow-up. This is a case where there is no single right answer. Ask why one option or another is offered to you. See also neoadjuvant and adjuvant therapy.

Advanced disease: IGCCCG risk groups

With metastases the risk group is determined by the IGCCCG system: site of the primary tumour, metastases outside the lungs and nodes, marker levels. For non-seminomatous tumours there are good, intermediate and poor prognosis groups; for seminoma, good and intermediate. The group determines the number of cycles and the intensity of chemotherapy.

Chemotherapy

The main regimen is BEP: bleomycin, etoposide and cisplatin.

Situation Typical regimen
Good prognosis 3 cycles of BEP (or 4 cycles of etoposide + cisplatin if bleomycin cannot be used)
Intermediate and poor prognosis 4 cycles of BEP
Seminoma IIA–IIB Radiotherapy or chemotherapy (3 cycles of BEP or 4 of EP)

Cycles are every 3 weeks, and it is very important not to delay them or reduce doses without need: in this disease effectiveness depends on dose intensity. Platinum drugs: platinum drugs. On the process in general: how chemotherapy is given.

Residual mass after chemotherapy

After treatment markers normalise, but a mass may remain in the nodes.

  • In non-seminomatous tumours residual masses over 1 cm are usually removed: they may contain teratoma or remnants of tumour. Such an operation should be done by an experienced surgeon.
  • In seminoma residual masses are more often watched, and PET-CT is used for assessment, no earlier than 6 weeks after chemotherapy (what PET-CT shows).

Recurrence

If the disease returns after chemotherapy, treatment is still curative for many patients. Other regimens are used (for example based on paclitaxel, ifosfamide and cisplatin) or high-dose chemotherapy with stem cell support. Such treatment should be given at a centre that does it often. This is one of the cases where a second opinion is especially important: progression on treatment.

Side effects

During treatment:

  • nausea and vomiting (nausea in chemotherapy);
  • low white cells (fever on chemotherapy);
  • hair loss (hair loss);
  • numb fingers and ringing in the ears from cisplatin (neuropathy);
  • lung damage from bleomycin: dry cough, shortness of breath. So lung function is assessed before treatment, smoking is avoided, and for operations and anaesthesia you must say you received bleomycin so the anaesthetist limits oxygen.

Long-term effects:

  • reduced fertility and testosterone level (hormones need monitoring);
  • higher risk of heart and vascular disease (blood pressure, cholesterol and weight need control);
  • hearing and kidney damage;
  • Raynaud's phenomenon (fingers turning white in the cold);
  • a slightly higher risk of second tumours;
  • risk of a tumour in the other testicle: it should be checked regularly.

Follow-up after treatment

The schedule depends on stage and risk, but the general principle is that visits are more frequent in the first years, with markers and CT, and less frequent later. Markers can rise before changes appear on CT. You should also check the remaining testicle yourself once a month and report any lump to your doctor.

What to ask your doctor

  • What is my tumour type and stage? What were the markers before and after surgery?
  • Was sperm stored?
  • Which risk group am I in?
  • What is recommended: surveillance, one course of chemotherapy or full BEP?
  • How many cycles, and how do we avoid breaking the schedule?
  • How will my lungs be monitored on bleomycin?
  • What is the follow-up schedule and which tests?
  • Which long-term effects should I have checked?

When to seek urgent help

  • temperature of 38 °C or above on chemotherapy;
  • shortness of breath or a dry cough that does not go away;
  • severe abdominal or back pain;
  • swelling and pain in one leg (see thrombosis in cancer);
  • severe nausea and vomiting when you cannot drink;
  • a lump in the remaining testicle.

Can I get a second opinion

Yes, and in germ cell tumours it often helps to avoid either unnecessary or insufficient treatment. Reasons: in stage I chemotherapy or radiotherapy is offered without discussing surveillance, markers were not measured, sperm was not stored, a mass remains after chemotherapy or the disease has recurred. Prepare the pathology, markers (before and after surgery), CT and summaries: documents for a second opinion, preparing for a consultation. If you need a review, book a consultation: I study the documents in advance and send a written summary. General information: urological tumours.

Sources

  1. Testicular Cancer Treatment (PDQ) — National Cancer Institute
  2. ESMO Clinical Practice Guidelines — ESMO
  3. Practical guidelines for drug treatment of malignant tumours — RUSSCO (Russian Society of Clinical Oncology)
  4. Clinical guidelines (Russia) — Russian Ministry of Health

Frequently asked questions

This article is for information only and does not replace a consultation with your treating doctor. Decisions about tests and treatment are made by the doctor who looks after you.